Physician profile
Patrick M Ignatius
NPI 1851398358
$366.91
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $74.69.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $169.50 | 2019-2020 | |
| Abbvie INC. | $76.29 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $25.74 | 2019-2020 | |
| Novo Nordisk INC | $23.21 | 2019 | |
| Amarin Pharma, INC. | $22.65 | 2019 | |
| Braintree Laboratories, INC. | $18.23 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.47 | 2019 | |
| Gilead Sciences, INC. | $14.82 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Ignatius listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.